Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions

International Journal of Neuropsychopharmacology

Volumn 3, Issue 1, 2000, Pages 13-25

  Angelucci, Francesco ^a,b   Aloe, Luigi ^b   Gruber, Susanne H M ^a   Fiore, Marco ^b,c   Mathé, Aleksander A ^a  

^a ST GÖRAN S HOSPITAL   (Sweden)

^b CNR   (Italy)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Antipsychotics; Choline acetyl transferase; Nerve growth factor; Neuropeptide Y; Rat brain

Indexed keywords

CHOLINE ACETYLTRANSFERASE; HALOPERIDOL; NERVE GROWTH FACTOR; NEUROLEPTIC AGENT; NEUROPEPTIDE Y; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; HYPOTHALAMUS; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NONHUMAN; OCCIPITAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RADIOIMMUNOASSAY; RAT; SEPTUM PELLUCIDUM;

EID: 0034121311     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145700001759     Document Type: Article

References (102)

1. Acquas E, Fibiger HC (1998). Dopaminergic regulation of striatal acetylcholine release: the critical role of acetylcholinesterase inhibition. Journal of Neurochemistry 70, 1088-1093.
2. Akoev G, Chalisova N, Ludino M, Terent'ev D, Yatsuk S, Romanjuk A (1996). Epileptiform activity increases the level of nerve growth factor in cerebrospinal fluid of epileptic patiens and in hippocampal neurons in tissue culture. Neuroscience 75, 601-605.
3. Alleva E, Aloe L, Bigi S (1993). An updated role for nerve growth factor in neurobehavioural regulation of adult vertebrates. Review of Neuroscience 4, 41-62.
4. Alleva E, Della Seta D, Cirulli F, Aloe L (1996). Haloperidol treatment decreases nerve growth factor levels in the hypothalamus of adult mice. Progress in Psychopharmacology and Biological Psychiatry 20, 483-489.
5. Aloe L, Alleva E, Bohm A, Levi-Montalcini R (1986). Aggressive behavior induces release of nerve growth factor from mouse salivary gland into the bloodtream. Neurobiology 83, 6184-6187.
6. Aloe L, Iannitelli A, Bersani G, Alleva E, Angelucci F, Maselli P, Manni L (1997). Haloperidol administration in human lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal. Neuropsychobiology 36, 65-68.
7. Aloe L, Tuveri M, Guerra G, Pinna P, Tirassa P, Micera A, Alleva E (1996). Changes in human plasma nerve growth factor level after chronic alcohol consumption and withdrawal. Alcoholism: Clinical and Experimental Research 20, 462-465.
8. Angelucci F, Cimino M, Balduini W, Pistillo L, Aloe L (1997). Prenatal ethanol exposure causes differential effects in the nerve growth factor and its receptors in basal forebrain of preweaning and adult rats. Journal of Neural Transplantation and Plasticity 6, 63-71.
9. Angelucci F, Fiore M, Cozzari C, Aloe L (1999). Prenatal ethanol effects on NGF level, NPY-, and ChAT-immunoreactivity in mouse entorhinal cortex: a preliminary study. Neurotoxicology and Teratolology 21, 415-425.
10. 3H]dopamine release from rat nucleus accumbens by neuropeptide Y may involve a Sigmal-like receptor. Journal of Pharmacology and Experimental Therapeutics 284, 553-560.
11. Barde YA (1989).Trophic factors and neuronal survival. Neuron 2, 1525-1534.
12. Bersani G, Aloe L, Iannitelli A, Maselli P, Alleva E, Angelucci F, Pancheri P (1999). Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizophrenia Research 37, 203-205.
13. Bouchard P, Tangui M, St-Pierre S, Privat A, Quirion R (1997). Neuropeptide Y and the calcitonin gene-related peptide attenuate learning impairments induced by MK-801 via sigma receptor-related mechanisms. European Journal of Neuroscience 9, 2142-2151.
14. Bracci-Laudiero L, Aloe L, Levi Montalcini R, Buttinelli C, Schilter D, Gillessen S, Otten U (1992). Multiple sclerosis patients express increased levels of β nerve growth factor in cerebrospinal fluid. Neuroscience Letters 147, 9-12.
15. Carnahan J, Nawa H (1995). Regulation of neuropeptide expression in the brain by neurotrophins: potential role in vivo. Molecular Neurobiology 10, 135-149.
16. Chronwall BM, DiMaggio DA, Massari VJ, Pickel VM, Ruggiero DA, O'Donohue TL (1985). The anatomy of neuropeptide-Y-containing neurons in the rat brain. Neuroscience 15, 1159-1181.
17. Cimino M, Cattabeni F, Di Luca M, Peruzzi G, Andena ML, Tirassa P, Angelucci F, Cozzari C, Aloe L (1996). Levels of NGF, p75 p75NGFR and ChAT immunoreactivity in brain of adult and aged microencephalic rats. Neurobiology of Aging 17, 137-142.
18. Cozzari C, Howard J, Hartman BK (1990). Analysis of epitopes on choline acetyltransferase using monoclonal antibodies. Abstract of American Society of Neuroscience 91 (6), 200.
19. Croll S, Wiengand S, Anderson K, Lindsay R, Nawa H (1994). Regulation of neuropeptides in adult rat forebrain by the neurotrophins BDNF and NGF. European Journal of Neuroscience 6, 1343-1353.
20. Dains K, Hitzemann B, Hitzemann R (1996). Genetics, neuroleptic response and the organization of cholinergic neurons in the mouse striatum. Journal of Pharmacology and Experimental Therapeutics 279, 1430-1438.
21. Dreyfus C, Bernd P, Martinez H, Rubin S, Black I (1989). GABAergic and cholinergic neurons exhibit high-affinty nerve growth factor binding in rat basal forebrain. Experimental Neurology 104, 181-185.
22. Drumheller A, Bouali S, Foumier A, St-Pierre S, Jolicoeur F (1994). Neurochemical effects of neuropeptide Y (NPY) and NPY2-36. Neuropeptides 27, 291-296.
23. Ebendal T (1992). Function and evolution in the NGF family and its receptors. Journal of Neuroscience Research 32, 461-470.
24. Ernfors P, Bengzon J, Kokaia Z, Persson H, Lindwall O (1991). Increased levels of messenger RNAs for neurotrophic factors in the brain during kindling epileptogenesis. Neuron 7, 165-176.
25. Falkai P, Bogerts B (1986). Cell loss in the hippocampus of schizophrenics. European Archives of Psychiatry and Neurological Science 236, 154-161.
26. Freedman R, Stromberg I, Seiger A, Olson L, Nordstrom AL, Wiesel FA, Bygdeman M, Wetmore C, Palmer MR, Hoffer BJ (1992). Initial studies of embryonic transplants of human hippocampus and cerebral cortex derived from schizophrenic women. Biological Psychiatry 32, 148-163.
27. Follesa P, Gale K, Mocchetti I (1994). Regional and temporal pattern of expression of nerve growth factor and basic fibroblast growth factor mRNA in rat brain following electroconvulsive shock. Experimental Neurology 127, 37-44.
28. Gall C, Murray K, Isackson P (1991). Kainic acid-induced seizures stimulate increased expression of nerve growth factor m RNA in rat hippocampus. Molecular Brain Research 9, 113-123.
29. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H (1996). Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. European Neuropsychopharmacology 6 (Suppl. 2), S13-20.
30. Garcia E, Rios C, Sotelo J (1992). Ventricular injection of nerve growth factor increases dopamine content in the striata of MPTP-treated mice. Neurochemisty Research 17, 979-982.
31. Garofalo L, Ribeiro-da-Silva A, Cuello AC (1992). Nerve growth factor-induced synaptogenesis and hypertrophy of cortical cholinergic terminals. Proceedings of the National Academy of Science, USA 89, 2639-2643.
32. 3H)dopa in various regions of the brain. Journal of Neurochemistry 13, 655-669.
33. Goebel S, Dietrich M, Jarry H, Wuttke W (1992). Indirect evidence to suggest that prolactin mediates the adrenal action of haloperidol to stimulate aldosterone and corticosterone secretion in rats. Endocrinology 130, 914-919.
34. Gruber S, Mathé AA (1997). Antipsychotics haloperidol and risperidone and psychotomimetic amphetamine affect neuropeptides and monoamines. Biological Psychiatry 42, 17.
35. Gruber S, Nomikos GG, Svensson TH, Mathé AA (1996). Effect of D-amphetamine and dopamine receptor antagonists on calcitonin gene-related peptide levels in ventral striatum. In: González-Mora JL, Borges R, Mas M (Eds.), Proceedings of 7th International Conference on In Vivo Methods, pp. 205-206. Tenerife, Spain.
36. Gruber S, Theodorsson E, Mathé AA (1998). Effects of amphetamine and phencyclidine on brain monoamines.and neuropeptides in haloperidol pretreated rats. Nord Journal Psychiatry 52, 127.
37. Hashimoto Y, Kawatsura H, Shiga Y, Furukawa S, Shigeno T (1992). Significance of nerve growth factor content levels after transient forebrain ischemia in gerbils. Neuroscience Letters 139, 45-46.
38. Hefti F (1986). Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. Journal of Neuroscience 6, 2155-2162.
39. Heilig M, Ekman R (1995). Chronic parenteral antidepressant treatment in rats: unaltered levels and processing of neuropeptide Y (NPY) and corticotropin-releasing hormone (CRH). Neurochemistry International 26, 351-355.
40. Heilig M, Vècséi L, Wahlestedt C, Ailing C, Widerlöv E (1990). Effects of centrally administered neuropeptide Y (NPY) and NPY13-36 on the brain monoaminergic systems of the rat. Journal of Neural Transmission 79, 193-208.
41. Heilig M, Widerlöv E (1995). Neurobiology and clinical aspects of neuropeptide Y. Critical Reviews in Neurobiology 9, 115-136.
42. Hertel P, Mathé JM, Nomikos GG, Iurlo M, Mathé AA, Svensson TH (1996). Effects of d-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behavioral Brain Research 72, 103-114.
43. Hökfelt T, Castel MN, Morino P, Zhang X, Dagerlind Å (1995). General overview of neuropeptides. In: Bloom FE, Kupfer DJ (Eds.), Psychopharmacology: The Fourth Generation of Progress (pp. 483-492). New York: Raven Press.
44. Iannitelli A, Aloe L, Bersani G, Maselli P, Angelucci F, Bracci-Laudiero L, Orsi P, Pancheri P (1995). Seizure-induced serum NGF levels increase after ECT in psychiatric patients: a first pilot study in man. Behavioral Pharmacology 6 (Suppl. 1), 93-94.
45. Joyce JN, Goldsmith SG, Gurevich EV (1997). Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes. Journal of Psychiatric Research 31, 197-217.
46. Kee KS, Kern RS, Marshall BD, Green MF (1998). Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophrenia Research 31, 159-165.
47. Kelley JJ, Gao XM, Tamminga CA, Roberts RC (1997). The effect of chronic haloperidol treatment on dendritic spines in the striatum. Experimental Neurology 146, 471-478.
48. Kerkerian-Le Goff L, Fomi C, Samuel D, Bloc A, Dusticier N, Nieoullon A (1992). Intracerebroventricular administration of neuropeptide Y affects parameters of dopamine, glutamate and GABA activities in the rat striatum. Brain Research Bulletin 28, 187-193.
49. Kern RS, Green MF, Marshall BD, Wirshing WC, Wirshing D, McGurk S, Marder SR, Mintz J (1998). Risperidone versus haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biological Psychiatry 44, 726-732.
50. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M (1999). Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacology 19, 57-61.
51. Kobayashi S, Ogren S, Ebendal T, Olson L (1997). Dopamine receptor antagonists block nerve growth factor-induced hyperactivity. European Journal of Pharmacology 326, 1-5.
52. Kyrkouli S, Stanley B, Leibowitz S (1992). Differential effects of galanin and neuropeptide Y on extracellular norepinephrine levels in the paraventricular hypothalamic nucleus of the rat: a microdialysis study. Life Science 51, 203-210.
53. Lauterborn, JC, Isackson PJ, Gall C (1994). Seizure-induced increases in NGF mRNA exibit different time courses across forebrain regions and are biphasic in hippocampus. Experimental Neurology 125, 22-40.
54. Levi-Montalcini R (1987). The nerve growth factor 35 years later. Science 237, 1154-1162.
55. Li S, Pelletier G (1986). The role of dopamine in the control of neuropeptide Y neurons in the rat arcuate nucleus. Neuroscience Letters 69, 74-77.
56. Lindefors N, Brené S, Herrera-Marschitz M, Persson H (1990). Neuropeptide gene expression in brain is differentially regulated by midbrain dopamine neurons. Experimental Brain Research 80, 489-500.
57. Lindwall O, Emfors P, Bengzon J, Kokaia Z, Smith M, Siesjo B, Perssson H (1992). Differential regulation of mRNAs for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the adult rat brain following cerebral ischemia and hypoglycemic coma. Proceedings of the National Academy of Science, USA 89, 648-652.
58. Liu W, Alreja M (1997). Atypical antipsychotics block the excitatory effects of serotonin in septohippocampal neurons in the rat. Neuroscience 79, 369-382.
59. Lo DC (1995). Neurotrophic factors and synaptic plasticity. Neuron 15, 979-981.
60. Lorigrados L, Alvarez P, Pavon N, Serrano T, Blanco L, Macias R (1996). NGF in experimental models of Parkinson disease. Molecular Chemistry of Neuropathology 28, 225-228.
61. Mahadik SP, Laev H, Korenovsky A, Karpiak SE (1988). Haloperidol alters rat CNS cholinergic system: enzymatic and morphological analyses. Biological Psychiatry 24, 199-217.
62. Mathé AA, Agren H, Lindstrom L, Theodorsson E (1994). Increased concentration of calcitonin gene-related peptide in cerebrospinal fluid of depressed patients. A possible trait marker of major depressive disorder. Neuroscience Letters 182, 138-142.
63. Mathé AA, Gruber S, Jimenez PA, Theodorsson E, Stenfors C (1997). Effects of electroconvulsive stimuli and MK-801 on neuropeptide Y, neurokinin A, and calcitonin gene-related peptide in rat brain. Neurochemical Research 22, 629-636.
64. Mathé AA, Hertel P, Nomikos GG, Gruber S, Mathé JM, Svensson TH (1996). The psychotomimetic drugs D-amphetamine and phencyclidine release calcitonin gene-related peptide in the limbic forebrain of the rats. Journal of Neuroscience Research 46, 316-323.
65. Mathé AA, Jousisto-Hanson J, Stenfors C, Theodorsson E (1990a). Effect of lithium on tachykinins, calcitonin gene-related peptide, and neuropeptide Y in rat brain. Journal of Neuroscience Research 26, 233-237.
66. Mathé AA, Stenfors C, Brodin E, Theodorsson E (1990b). Neuropeptides in brain: effects of microwave irradiation and decapitation, Life Science 46, 287-293.
67. Midgley L, Bush L, Gibb J, Hanson G (1993). Differential regulation of neuropeptide Y systems in limbic structures of the rat. Journal of Pharmacology and Experimental Therapeutics 267, 707-713.
68. Midgley L, Wagstaff J, Singh N, Bush L, Gibb J, Hanson G (1994). Dynamic dopaminergic regulation of neuropeptide Y systems in discrete striatal and accumbens regions. European Journal of Pharmacology 251, 191-199.
69. Mohammed A, Winblad B, Ebendal T, Larkfors L (1990). Environmental influence on behaviour and nerve growth factor in the brain. Brain Research 528, 62-72.
70. Nanko S, Hattori M, Kuwata S, Sasaki T, Fukuda R, Dai XY, Yamaguchi K, Shibata Y, Kazamatsuri H (1994) Neurotrophin-3 gene polymorphism associated with schizophrenia. Acta Psychiatrica Scandinavica 89, 390-392.
71. Nawa H, Camahan J, Gall C (1995). BDNF protein measured by a novel enzyme immunoassay in normal brain and after seizure: partial disagreement with mRNA levels. European Journal of Neuroscience 7, 1527-1535.
72. Nemeroff C, Levant B, Myers B, Bissette G (1992). Neurotensin, antipsychotic drugs, and schizophrenia: basic and clinical studies. Annals of the New York Academy of Science 668, 146-156.
73. Nibuya M, Morinobu S, Duman RS (1995). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. Journal of Neuroscience 15, 7539-7547.
74. Nishio T, Furukawa S, Akiguchi I, Sunohara N (1998). Medial nigral dopamine neurons have rich neurotrophin support in humans. NeuroReport 9, 2847-2851.
75. Obuchowicz E (1996). Long-term treatment with chlorpromazine and haloperidol but not with sulpiride and clozapine markedly elevates neuropeptide Y-like immunoreactivity in the rat hypothalamus. Neuropeptides 30, 471-478.
76. Ozaki T, Mui K, Yamagami S (1999). Comparison of the effects of dopamine D1 and D2 receptor antagonists on nerve growth factor mRNA expression. European Journal of Pharmacology 369, 133-143.
77. Pavia J, Hastings J, Morris M (1995). Neuropeptide Y potentiation of potassium-induced noradrenaline release in the hypothalamic paraventricular nucleus of the rat in vivo. Brain Research 690, 108-111.
78. Prakash N, Cohen-Cory S, Frostig RD (1996). Rapid and opposite effects of BDNF and NGF on the functional organization of the adult cortex. Nature 381, 702-706.
79. Reynold G (1997). What is an atypical antipsychotic? Journal of Psychopharmacology 11, 195-199.
80. Richardson RD, Boswell T, Raffety BD, Seeley RJ, Wingfield JC, Woods SC (1995). NPY increases food intake in white-crowned sparrows : effect in short and long photoperiods. American Journal of Physiology 268, R1418-R1422.
81. Rylett RJ, Williams LR (1994). Role of neurotrophins in cholinergic-neurone function in the adult and aged CNS. Trends in Neuroscience 17, 486-490.
82. Sakai K, Maeda K, Chihara K, Kaneda H (1995). Increases in cortical neuropeptide Y and somatostatin concentrations following haloperidol-depot treatment in rats. Neuropeptides 29, 157-161.
83. Seiler M, Schwab M (1983). Specific retrogade transport of nerve growth factor from neocortex to nucleus basalis in the rat. Brain Research 266, 225-232.
84. Shelton DL, Reichardt LF (1986). Studies on the expression of the b nerve growth factor (NGF) gene in the central nervous system: level and regional distribution of NGF mRNA suggest that NGF functions as a trophic factor for several distinct populations of neurons. Proceedings of the National Academy of Science, USA 83, 2714-2718.
85. Shibasaki T, Tsumori C, Hotta M, Imaki T, Demura H (1995). Intracerebroventricular administration of neuropeptide Y inhibits release of noradrenaline in the hypothalamic paraventricular nucleus caused by manual restraint in the rat through opioid system. Brain Research 688, 189-192.
86. Smialowska M (1995). An inhibitory dopaminergic regulation of the neuropeptide Y immunoreactivity expression in the rat cerebral cortex neurons. Neuroscience 66, 589-595.
87. Spenger C, Hyman C, Studer L, Egli M, Evtouchenko L, Jackson C, Dahl-Jorgensen A, Lindsay RM, Seyler RW (1995). Effects of BDNF on dopaminergic, serotoninergic and GABAergic neurons in cultures of human fetal ventral mesencephalon. Experimental Neurology 133, 50-63.
88. Springer J, Gwag B, Sessler F (1994). Central administration of the excitotoxin NMDA increases nerve growth factor mRNA in vivo. Neurotoxicology 15, 483-490.
89. Stenfors C, Theodorsson E, Mathé AA (1989). Effect of repeated electroconvulsive treatment on regional concentrations of tachykinins, neurotensin, vasoactive intestinal polypeptide, neuropeptide Y, and galanin in rat brain. Journal of Neuroscience Research 24, 445-450.
90. Strauss S, Otten U, Joggerst B, Pluss K, Volk B (1994). Increased levels of nerve growth factor protein and mRNA and reactive gliosis following kainic acid injection into the rat striatum. Neuroscience Letters 168, 193-196.
91. Theodorsson E, Stenfors C, Mathé AA (1990). Microwave irradiation increases recovery of neuropeptides from brain tissues. Peptides 11, 1191-1197.
92. Thoenen H (1995). Neurotrophins and neuronal plasticity. Science 270, 593-598.
93. Thoenen H, Bandtlow C, Heumann R (1987). The physiological function of nerve growth factor in the central nervous system: comparison with the periphery. Review of Physiological and Biochemical Pharmacology 109, 145-178.
94. Ushijima I, Kawano M, Kaneyuki H, Suetsugi M, Usami K, Hirano H, Mizuki Y, Yamada M (1997). Dopaminergic and cholinergic interaction in cataleptic responses to mice. Pharmacology, Biochemistry and Behavior 58, 103-108.
95. Van Putten T, Marder SR, Mintz J (1991). Serum prolactin as a correlate of clinical response to haloperidol. Journal of Clinical Psychopharmacology 11, 357-361.
96. Vedder H, Affolter H, Otten U (1993). Nerve growth factor regulates tachykinin gene expression and biosynthesis in rat sensory neurons during early postnatal development. Neuropeptides 24, 351-357.
97. Verge V, Richardson P, Wiesenfeld Z, Hokfelt T (1995). Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. Journal of Neuroscience 15, 2081-2096.
98. Wahlestedt C, Heilig M (1995). Neuropeptide Y and related peptides. In: Bloom FE, Kupfer DJ (Eds.), Psychopharmacology : The Fourth Generation of Progress (pp. 543-551). New York: Raven Press.
99. Wahlestedt C, Karoum F, Jaskiw G, Wyatt R, Larhammar D, Ekman R, Reis D (1991). Cocaine-induced reduction of brain neuropeptide Y synthesis dependent on medial prefrontal cortex. Proceedings of the National Academy of Science, USA 88, 2078-2082.
100. Weinberger DR (1999) Cell biology of the hippocampal formation in schizophrenia. Biological Psychiatry 45, 395-402.
101. Weskamp G, Otten U (1986). An enzyme-linked immunoassay for nerve growth factor (NGF): a tool for studying regulatory mechanisms involved in NGF production in brain and peripheral tissues. Journal of Neurochemistry 48, 1779-1786.
102. Yntema OP, Korf J (1987). Transient suppression by stress of haloperidol induced catalepsy by the activation of the adrenal medulla. Psychopharmacology 91, 131-134.